{"type":"trials","record":{"id":86136,"source_id":"isrctn","external_id":"ISRCTN40126490","title":"Evaluating a new high‑dose aflibercept injection for people with polypoidal choroidal vasculopathy that has not responded well to standard care","brief_summary":"Primary objective To determine the proportion of eyes with absence of PCV activity at week 24 compared to baseline following treatment with aflibercept 8mg Secondary objective To evaluate BCVA change at week 24 of intervention compared to baseline BCVA To determine proportion of complete PCV regression at week 24 compared to baseline To determine the reduction in PED height at week 24 compared to baseline To explore imaging and clinical biomarkers associated with disease activity and treatment response.","overall_status":"Not Yet Recruiting","phases":["Phase IV"],"study_type":"Interventional","sponsor":"Moorfields Eye Hospital NHS Foundation Trust","enrollment":0,"countries":["United Kingdom","England"],"start_date":"2026-10-01","completion_date":"2027-10-01","last_update_date":"2026-08-28","source_url":"https://www.isrctn.com/ISRCTN40126490","editorial_summary":"A registered Phase IV study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:45:21.717702+00:00","last_seen_at":"2026-09-25T06:04:08.096+00:00","metadata":{"sex":"All","age_range":"Mixed","comparator":null,"attribution":"Source: ISRCTN ISRCTN40126490; retrieved 2026-09-25","interventions":["Aflibercept 8mg (Eylea 8mg)","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":[],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Neovascular age-related macular degeneration Polypoidal choroidal vasculopathy","The intervention is Aflibercept 8mg (Eylea 8mg) - Eylea 114.3 mg/ml solution for injection. Treatment is in a pre-fille…","Participant information sheet","Protocol file","Aflibercept 8mg (Eylea 8mg)","Drug"],"relevance_confidence":62,"source_quality_score":98,"freshness_score":100,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:04:08.423365+00:00","duplicate_cluster_key":"id:isrctn40126490","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-10-01 to 2027-10-01","comparator":null,"confidence":"structured-source","population":"All · Mixed","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:04:08.098Z","intervention":["Aflibercept 8mg (Eylea 8mg)","Drug"],"participants":0,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase IV","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":[],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: aging.","Study type is explicitly identified as Interventional."],"matched_fields":["controlled terminology","abstract context","study type"],"relevance_score":62,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/86136","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}